Transcript PowerPoint with slides and notes

Minnesota Department of Health
Tuberculosis Prevention and Control Program
(651) 201-5414
Tuberculosis surveillance data for Minnesota are available on the
Web at: www.health.state.mn.us/tb
Year
2010
No. Cases
135
Rate*
2.5
2011
2012
2013
2014
137
162
151
147
2.6
3.0
2.8
2.7
* Cases per 100,000 population. Rates were calculated using state
population estimates from the U.S. Census Bureau.
Year of Diagnosis
Percentage of Cases
Year
2010
2011
No. Cases
135
137
No. Deaths* (%)
3 (2%)
9 (7%)
2012
2013
2014
162
151
147
4 (2%)
2 (1%)
3 (2%)
*Represents only deaths due to TB disease or TB drug-induced toxicity
Location of Residence
2010
No. (rate)*
2011
No. (rate)*
2012
No. (rate)*
2013
2014
No. (rate)* No. (rate)*
Hennepin County
67 (5.8)
59 (5.0)
71 (6.1)
51 (4.3)
51 (4.3)
Ramsey County
34 (6.7)
31 (6.0)
39 (7.6)
39 (7.5)
26 (4.9)
Suburban Twin Cities
Metro†
16 (1.3)
12 (0.7)
27 (2.2)
20 (1.6)
24 (2.0)
Olmsted County
6 (4.2)
9 (6.2)
3 (2.1)
10 (6.8)
16 (10.7)
Other counties
12 (0.5)
26 (1.1)
22 (1.0)
31 (1.3)
30 (1.3)
Total
135 (2.5)
137 (2.6)
162 (3.0)
151 (2.8)
147 (2.7)
* Rate per 100,000 population. Rates were calculated using population estimates from
U.S. Census Bureau data.
† Anoka, Carver, Dakota, Scott, and Washington counties
Location of Residence
2010
No. (rate)*
2011
No. (rate)*
2012
No. (rate)*
Hennepin County
67 (50)
59 (43)
71 (44)
51 (34)
51 (35)
Ramsey County
34 (25)
31 (22)
39 (24)
39 (26)
26 (18)
Suburban Twin Cities
Metro†
16 (12)
12 ( 9)
27 (17)
20 (13)
24 (16)
Olmsted County
6 ( 4)
9 ( 7)
3 ( 2)
10 ( 7)
16 (11)
Other counties
12 ( 9)
26 (19)
22 (13)
31 (21)
30 (20)
135 (100)
137 (100)
162 (100)
151 (100)
147 (100)
Total
2013
2014
No. (rate)* No. (rate)*
* Rate per 100,000 population. Rates were calculated using population
estimates from U.S. Census Bureau data.
† Anoka, Carver, Dakota, Scott, and Washington counties
Hennepin: 51
Ramsey: 26
Suburban metro: 24
Greater MN: 46
Total: 147
Hennepin: 299
Ramsey: 169
Suburban metro: 99
Greater MN: 165
Total: 732
Place of Birth
Percentage of Cases
N = 732
Cases per 100,000 †
* Race categories do not include persons of Hispanic/Latino origin.
† Rates were calculated using population estimates from the U.S. Census Bureau.
** The 2014 patient with multiple races is not represented in this graph.
Race / Ethnicity*
Foreign-Born Cases
No. (%)
U.S.-Born Cases†
No. (%)
White
15 (2)
59 (42)
Black
308 (52)
35 (25)
Asian
211 (36)
14 (10)
Native American / Alaska Native
0
17 (12)
Multi-racial
0
1 (<1)
59 (10)
13 (9)
593 (100)
139 (100)
Hispanic/Latino
Total
*Race categories do not include persons of Hispanic/Latino origin.
†Includes
U.S.-born children of foreign-born parents
Risk Category*
2010
(N=135)
No. (%)
2011
(N=137)
No. (%)
2012
(N=162)
No. (%)
2013
(N=151)
No. (%)
2014
(N=147)
No. (%)
Cumulative
(N=732)
No. (%)
Foreign-born
110 (81)
116 (85)
136 (84)
123 (81)
108 (73)
593 (81)
Substance abuse†
7 (5)
7 (5)
7 (4)
9 (6)
7 (5)
37 (5)
Homeless
3 (2)
2 (1)
2 (1)
4 (3)
7 (5)
18 (2)
HIV-infected
6 (4)
3 (2)
6 (4)
4 (3)
4 (3)
23 (3)
23 (17)
27 (20)
20 (12)
35 (23)
37 (25)
142 (19)
Incarcerated
4 (3)
2 (1)
0 (0)
0 (0)
1 (1)
7 (1)
Long-term care resident
3 (2)
2 (1)
1 (1)
2 (1)
0 (0)
8 (1)
Other medical
condition**
* Risk categories are not mutually exclusive
Alcohol abuse and/or illicit drug use
** Conditions or therapies that increase risk for progression from latent TB
infection to active TB disease, not including HIV/AIDS
†
N=732
* Risk categories are not mutually exclusive
† Alcohol abuse and/or illicit drug use
** Conditions or therapies that increase risk for progression from latent TB
infection to active TB disease, not including HIV/AIDS
Medical conditions**
Cases
(N=732)
No. (%)
Diabetes
81 (11)
End stage renal disease
19 (3)
Weight loss/undernutrition/malabsorption
6 (1)
Other: silicosis, hematologic disease
3 (<1)
Other immunosuppressive condition or
immunosuppressive therapy***
56 (8)
*Conditions or therapies that increase risk for progression from latent TB
infection to active TB disease, not including HIV/AIDS
**Patients could have > 1 medical condition
***Includes TNF α antagonist therapy and post-organ transplantation
* Risk categories are not mutually exclusive
** Conditions or therapies  risk for progression to active TB disease, not HIV
† Alcohol abuse and/or illicit drug use
Foreign-Born
Cases
No. (%)
U.S.-Born
Cases
No. (%)
Total
No. (%)
Negative
546 (92)
126 (91)
672 (92)
Positive
21 (4)
2 (1)
23 (3)
Refused
4 (1)
2 (1)
6 (1)
Not Offered
22 (4)
9 (6)
31 (4)
593 (100)
139 (100)
732 (100)
HIV Status
Total
Percent co-infected
No. of TBHIV cases
in MN:
2005 – 12
2006 – 8
2007 – 12
2008 – 11
2009 – 7
2010 – 6
2011 – 3
2012 – 6
2013 – 4
2014 – 4
No. of eligible TB cases*
Percent of eligible TB cases
with HIV result
* Alive at diagnosis
School/Setting
No. (%)
Preschool
2 (<1)
Elementary
36 (5)
Secondary
31 (4)
Post-secondary
51 (7)
Other*
52 (7)
None
560 (77)
Total
732 (100)
*Includes: daycare, ESL/ELL, and other schools
Number of Cases
Year
* “Other” includes: Eastern Europe, North Africa/Middle East, and Western
Europe
Number of Cases
Region of Birth
* “Other” includes: Eastern Europe, North Africa/Middle East, and Western
Europe
N = 593
N = 593
N = 71
* Per results of pre-immigration screening performed overseas
N = 593
% of foreign-born cases
N=
175
203
155
129
110
116
136
123
108
Technical instructions for overseas exams revised
N = 732
* Includes cases with or without concurrent pulmonary disease
Site of disease**
Cases
(N=356)
No. (%)
Lymphatic
192 (54)
Musculoskeletal
51 (14)
Pleural
40 (11)
Peritoneal
22 (6)
Genitourinary
14 (4)
Brain
14 (4)
Meningeal
11 (3)
Other
26 (7)
* Includes TB cases with or without concurrent pulmonary disease
** Patients may have multiple extrapulmonary sites of disease
N = 460
* From initial chest x-ray or chest CT scan
N = 460
*53% of pulmonary cases without sputum smear results were under 15
years of age
N = 732
N = 732
*Based on the public health surveillance definition for TB
[CDC. (2009, June) CDC Tuberculosis Surveillance Data Training: Report of Verified
Case of Tuberculosis (RVCT) Instruction Manual. Atlanta, GA: U.S. Department of Health
and Human Services, CDC. (Appendix A - Tuberculosis Case Definition for Public Health
Surveillance)]
Year
Cases With
Susceptibility
Results*
Any Drug
Resistance†
No. (%)
INHResistant**
No. (%)
MDR-TB‡
No. (%)
2010
109
13 (12)
5 (5)
0 (0)
2011
101
22 (22)
12 (12)
3 (3)
2012
124
23 (19)
12 (10)
1 (1)
2013
113
24 (21)
13 (21)
0 (0)
2014
105
25 (24)
19 (18)
1 (1)
Total
552
107 (19)
61 (11)
5 (1)
* Culture-confirmed cases with drug susceptibility results available
† Resistance to at least one first-line anti-TB drug [i.e., isoniazid (INH), rifampin,
pyrazinamide (PZA), or ethambutol]
** INH-resistant cases may also be resistant to other drugs
‡ Multi-drug resistant TB, defined as resistance to at least INH and rifampin
Place of birth
Cases With
Any Drug
Susceptibility Resistance†
Results*
No. (%)
INHResistant**
No. (%)
MDR-TB‡
No. (%)
Foreign-Born Cases
456
94 (21)
53 (12)
4 (1)
U.S.-Born Cases
96
13 (14)
8 (8)
1 (1)
Total
552
107 (19)
61 (11)
5 (1)
* Culture-confirmed cases with drug susceptibility results available
† Resistance to at least one first-line anti-TB drug [i.e., isoniazid (INH), rifampin,
pyrazinamide (PZA), or ethambutol]
** INH-resistant cases may also be resistant to other drugs
‡ Multi-drug resistant TB, defined as resistance to at least INH and rifampin
N = 732
Overseas TB class follow-up
2%
* “Other” includes: other immigration exam – 1.3%, and employment
screening (including health care worker screening) – 1.6%
90%
90%
N=722
Type of provider
* DOT = Directly Observed Therapy
started on
treatment
Year
Started
Treatment*
Completed
Within 12 mos.**
No. (%)
Completed
Overall**
No. (%)
2010
116
105 (91)
115 (99)
2011
101
96 (95)
97 (96)
2012
133
127 (95)
130 (98)
2013
125
116 (93)
123 (98)
Total
475
444 (93)
465 (98)
* Patients for whom < 12 months of therapy is indicated. This excludes:
patients with rifampin resistance, meningeal TB, TB in bone or skeletal system,
TB in CNS, children 14 years of age or younger with disseminated TB, patients
who died or moved out of US within 366 days of starting treatment.
** Treatment completion data as of 9/14/2015
* Some patients are managed by multiple providers throughout disease course